Body composition and lung cancer-associated cachexia in TRACERx

Abstract

Cancer-associated cachexia (CAC) is a major contributor to morbidity and mortality in individuals with non-small cell lung cancer. Key features of CAC include alterations in body composition and body weight. Here, we explore the association between body composition and body weight with survival and delineate potential biological processes and mediators that contribute to the development of CAC. Computed tomography-based body composition analysis of 651 individuals in the TRACERx (TRAcking non-small cell lung Cancer Evolution through therapy (Rx)) study suggested that individuals in the bottom 20th percentile of the distribution of skeletal muscle or adipose tissue area at the time of lung cancer diagnosis, had significantly shorter lung cancer-specific survival and overall survival. This finding was validated in 420 individuals in the independent Boston Lung Cancer Study. Individuals classified as having developed CAC according to one or more features at relapse encompassing loss of adipose or muscle tissue, or body mass index-adjusted weight loss were found to have distinct tumor genomic and transcriptomic profiles compared with individuals who did not develop such features. Primary non-small cell lung cancers from individuals who developed CAC were characterized by enrichment of inflammatory signaling and epithelial-mesenchymal transitional pathways, and differentially expressed genes upregulated in these tumors included cancer-testis antigen MAGEA6 and matrix metalloproteinases, such as ADAMTS3. In an exploratory proteomic analysis of circulating putative mediators of cachexia performed in a subset of 110 individuals from TRACERx, a significant association between circulating GDF15 and loss of body weight, skeletal muscle and adipose tissue was identified at relapse, supporting the potential therapeutic relevance of targeting GDF15 in the management of CAC.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 78

1. 1.

   Martin L, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2013;31:1539-1547.

   Not in our library10.1200/jco.2012.45.2722

2. 2.

   Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. The New England journal of medicine. 2003;348:1625-1638.

   Not in our library10.1056/nejmoa021423

3. 3.
   Body mass index and mortality in chronic obstructive pulmonary disease · 2016

   No notice
4. 4.

   Lavie CJ, McAuley PA, Church TS, Milani RV, Blair SN. Obesity and cardiovascular diseases: implications regarding fitness, fatness, and severity in the obesity paradox. J Am Coll Cardiol. 2014;63:1345-1354.

   Not in our library10.1016/j.jacc.2014.01.022

5. 5.

   Baracos VE, Martin L, Korc M, Guttridge DC, Fearon KCH. Cancer-associated cachexia. Nature Reviews Disease Primers. 2018;4:17105.

   Not in our library10.1038/nrdp.2017.105

6. 6.

   Fearon K, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489-495.

   Not in our library10.1016/s1470-2045(10)70218-7

7. 7.

   Caan BJ, et al. Association of Muscle and Adiposity Measured by Computed Tomography With Survival in Patients With Nonmetastatic Breast Cancer. JAMA Oncol. 2018;4:798-804.

   Not in our library10.1001/jamaoncol.2018.0137

8. 8.

   Lee JS, et al. Subcutaneous Fat Distribution is a Prognostic Biomarker for Men with Castration Resistant Prostate Cancer. J Urol. 2018;200:114-120.

   Not in our library10.1016/j.juro.2018.01.069

9. 9.

   Brown JC, et al. The deterioration of muscle mass and radiodensity is prognostic of poor survival in stage I-III colorectal cancer: a population-based cohort study (C-SCANS). J Cachexia Sarcopenia Muscle. 2018;9:664-672.

   Not in our library10.1002/jcsm.12305

10. 10.

    Baracos VE, Reiman T, Mourtzakis M, Gioulbasanis I, Antoun S. Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis. Am J Clin Nutr. 2010;91:1133s-1137s.

    Not in our library10.3945/ajcn.2010.28608c

11. 11.

    Yang M, Shen Y, Tan L, Li W. Prognostic Value of Sarcopenia in Lung Cancer: A Systematic Review and Meta-analysis. Chest. 2019;156:101-111.

    Not in our library10.1016/j.chest.2019.04.115

12. 12.
    Sub-cutaneous Fat Mass measured on multislice computed tomography of pretreatment PET/CT is a prognostic factor of stage IV non-small cell lung cancer treated by nivolumab · 2019

    Not checked
13. 13.

    Tan H, et al. Preoperative Body Composition Combined with Tumor Metabolism Analysis by PET/CT Is Associated with Disease-Free Survival in Patients with NSCLC. Contrast Media Mol Imaging. 2022;2022:7429319.

    Not in our library10.1155/2022/7429319

14. 14.

    Shen W, et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol (1985). 2004;97:2333-2338.

    Not in our library10.1152/japplphysiol.00744.2004

15. 15.

    Shen W, et al. Visceral adipose tissue: relations between single-slice areas and total volume. Am J Clin Nutr. 2004;80:271-278.

    Not in our library10.1093/ajcn/80.2.271

16. 16.

    Mourtzakis M, et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008;33:997-1006.

    Not in our library10.1139/h08-075

17. 17.

    Jamal-Hanjani M, et al. Tracking the Evolution of Non-Small-Cell Lung Cancer. The New England journal of medicine. 2017;376:2109-2121.

    Not in our library10.1056/nejmoa1616288

18. 18.

    Frankell Alexander M, Al Bakir Maise, Lim Emilia L, Karasaki Takahiro, Ward Sophia, Veeriah Selvaraju, Huebner Emma Colliver Ariana, Bunkum Abigail, Hill Mark S, Grigoriadis Kristiana, Moore David A, et al. The natural history of NSCLC and impact of subclonal selection in TRACERx. Nature. 2023.

    Not in our library

19. 19.

    Christiani D. Boston Lung Cancer Study. 2022.

    Not in our library

20. 20.

    Anyene I, et al. Body composition from single versus multi-slice abdominal computed tomography: Concordance and associations with colorectal cancer survival. J Cachexia Sarcopenia Muscle. 2022.

    Not in our library10.1002/jcsm.13080

21. 21.

    Dabiri S, et al. Deep learning method for localization and segmentation of abdominal CT. Comput Med Imaging Graph. 2020;85:101776.

    Not in our library10.1016/j.compmedimag.2020.101776

22. 22.

    Bridge CP, Stoyanov D, et al. OR 2.0 Context-Aware Operating Theaters, Computer Assisted Robotic Endoscopy, Clinical Image-Based Procedures, and Skin Image Analysis. 2018;204-213.

    Not in our library

23. 23.

    Martin L, et al. Diagnostic Criteria for the Classification of Cancer-Associated Weight Loss. Journal of Clinical Oncology. 2014;33:90-99.

    Not in our library10.1200/jco.2014.56.1894

24. 24.

    Speliotes EK, et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nature genetics. 2010;42:937-948.

    Not in our library10.1038/ng.686

25. 25.

    Locke AE, et al. Genetic studies of body mass index yield new insights for obesity biology. Nature. 2015;518:197-206.

    Not in our library10.1038/nature14177

26. 26.

    Wen W, et al. Meta-analysis of genome-wide association studies in East Asian-ancestry populations identifies four new loci for body mass index. Hum Mol Genet. 2014;23:5492-5504.

    Not in our library10.1093/hmg/ddu248

27. 27.

    Akiyama M, et al. Genome-wide association study identifies 112 new loci for body mass index in the Japanese population. Nature genetics. 2017;49:1458-1467.

    Not in our library10.1038/ng.3951

28. 28.
    The Influence of Age and Sex on Genetic Associations with Adult Body Size and Shape: A Large-Scale Genome-Wide Interaction Study · 2015

    Corrected
29. 29.

    Johns N, et al. New genetic signatures associated with cancer cachexia as defined by low skeletal muscle index and weight loss. J Cachexia Sarcopenia Muscle. 2017;8:122-130.

    Not in our library10.1002/jcsm.12138

30. 30.

    Solheim TS, et al. Is there a genetic cause for cancer cachexia? - a clinical validation study in 1797 patients. Br J Cancer. 2011;105:1244-1251.

    Not in our library10.1038/bjc.2011.323

31. 31.

    Baranski TJ, et al. A high throughput, functional screen of human Body Mass Index GWAS loci using tissue-specific RNAi Drosophila melanogaster crosses. PLOS Genetics. 2018;14:e1007222.

    Not in our library10.1371/journal.pgen.1007222

32. 32.

    Lodge W, et al. Tumor-derived MMPs regulate cachexia in a Drosophila cancer model. Dev Cell. 2021;56:2664-2680.

    Not in our library10.1016/j.devcel.2021.08.008

33. 33.

    Ding G, et al. Coordination of tumor growth and host wasting by tumor-derived Upd3. Cell Rep. 2021;36:109553.

    Not in our library10.1016/j.celrep.2021.109553

34. 34.

    Kwon Y, et al. Systemic organ wasting induced by localized expression of the secreted insulin/IGF antagonist ImpL2. Dev Cell. 2015;33:36-46.

    Not in our library10.1016/j.devcel.2015.02.012

35. 35.

    Song W, et al. Tumor-Derived Ligands Trigger Tumor Growth and Host Wasting via Differential MEK Activation. Dev Cell. 2019;48:277-286.

    Not in our library10.1016/j.devcel.2018.12.003

36. 36.

    Newton H, et al. Systemic muscle wasting and coordinated tumour response drive tumourigenesis. Nature Communications. 2020;11:4653.

    Not in our library10.1038/s41467-020-18502-9

37. 37.

    Figueroa-Clarevega A, Bilder D. Malignant Drosophila tumors interrupt insulin signaling to induce cachexia-like wasting. Dev Cell. 2015;33:47-55.

    Not in our library10.1016/j.devcel.2015.03.001

38. 38.

    Kim J, et al. Tumor-induced disruption of the blood-brain barrier promotes host death. Dev Cell. 2021;56:2712-2721.

    Not in our library10.1016/j.devcel.2021.08.010

39. 39.
    GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers · 2011

    No notice
40. 40.

    Bentham R, et al. Using DNA sequencing data to quantify T cell fraction and therapy response. Nature. 2021;597:555-560.

    Not in our library10.1038/s41586-021-03894-5

Cited by papers we hold 1

• Efficacy prediction of neoadjuvant cadonilimab plus FLOT therapy for advanced gastric cancer: a study based on body composition changes · 2025
  Not checked

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.